Methods and compositions for generating human erythroid progenitor cells

A chemically defined culture medium using signaling pathway modulators efficiently generates erythroid progenitor cells from hematopoietic stem cells in a cost-effective and time-reduced manner, addressing inefficiencies in existing protocols.

JP2024542842AInactive Publication Date: 2024-11-15TRAILHEAD BIOSYSTEMS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024534161
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-08
Filing Date
2022-12-06
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current methods for generating human erythroid progenitor cells from hematopoietic stem cells are inefficient and costly, particularly due to the use of expensive reagents like stem cell factor (SCF) and require lengthy protocols.

Method used

A chemically defined culture medium using small molecule agents that agonize or antagonize specific signaling pathways, such as IL3R, TGFβ, AHR, RET, and AKT pathways, to promote erythroid differentiation, eliminating the need for SCF and reducing production time to 9 days.

Benefits of technology

The method significantly reduces production time and costs while achieving high yields of erythroid progenitor cells, capable of further differentiation into red blood cells and platelets, with improved control over culture conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542842000001_ABST
    Figure 2024542842000001_ABST
Patent Text Reader

Abstract

A method is provided for inducing human erythroid progenitor cells from hematopoietic stem cells using a chemically defined culture medium. The erythroid progenitor cells produced by the method include megakaryocyte / erythroid progenitor cells (MEP cells) and CD71+CD235+CD34- erythroid cells, which can be further differentiated into erythrocytes. Culture media, isolated cell populations, and kits are also provided. TIFF2024542842000005.tif91145
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims priority to U.S. Provisional Application No. 63 / 287,372, filed December 8, 2021, the entire contents of which are incorporated herein by reference. [Background technology]

[0002] 2. Background of the Invention Hematopoietic stem cells (HSCs) are pluripotent and self-renewing cells from which the entire hematopoietic system originates. HSCs are rare cells that are naturally found in bone marrow and umbilical cord blood, and are even rarer in peripheral blood. HSCs are typically defined by the expression or non-expression of certain markers, including the expression of CD34, and the non-expression of lineage-specific markers and CD38 (Lin-CD34+CD38-). The culture conditions in which HSCs grow determine which cell lineages they differentiate into downstream of the hematopoietic system. Therefore, there is great interest in identifying culture conditions that promote the production of specific hematopoietic lineages.

[0003] Under appropriate conditions, HSCs can differentiate into blood components, including red blood cells and platelets. Because blood products for transfusion are always in short supply everywhere, and donated blood is concerned about being contaminated by existing and emerging pathogens, the ability to generate blood components from HSCs in vitro is a focus in regenerative medicine.

[0004] The earliest protocols for generating RBCs from CD34+ HSCs identified interleukin-3 (IL-3), erythropoietin (EPO), and stem cell factor (SCF) as key culture components for developing erythroid lineages (see, e.g., Giarratana et al. (2011) Blood 118:5071-5079; Kim (2014) Yonsei Med. J. 55:304-309). However, SCF is an expensive reagent, and therefore SCF-containing culture media for generating erythroid progenitors are expensive compared to media without SCF.

[0005] Additional protocols for generating erythrocytes from CD34+ HSCs have been described, which further define the components for specific stages of differentiation. For example, a 21-day, four-stage protocol for generating erythroid cells has been described, which utilizes culture components including IL-3, EPO, and SCF, as well as thrombopoietin (TPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), and fms-related tyrosine kinase 3 ligand (FL), and also bovine serum (Zhang et al. (2017) Stem Cells Transl. Med. 6:1698-1709). Protocols for serum-free differentiation of erythroid cells have been described, in which dexamethasone, insulin, holotransferrin, and bovine serum albumin are included in the culture medium in addition to the use of IL-3, EPO, and SCF (Uchida et al. (2018) Mol. Ther. Methods Clin. Dev. 9:247-256).

[0006] Thus, despite some progress, there remains a need for efficient and stable methods and compositions for generating human erythroid progenitor cells from human hematopoietic stem cells in culture. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Giarratana et al. (2011) Blood 118:5071-5079 [Non-Patent Document 2] Kim (2014) Yonsei Med. J. 55:304-309 [Non-Patent Document 3] Zhang et al. (2017) Stem Cells Transl. Med. 6:1698-1709 [Non-Patent Document 4] Uchida et al. (2018) Mol. Ther. Methods Clin. Dev. 9:247-256 Summary of the Invention

[0008] The present disclosure provides a method for generating human erythroid progenitor cells from human CD34+ hematopoietic stem cells (HSCs), such as those derived from umbilical cord blood or bone marrow cells, using a chemically defined culture medium. The present disclosure provides a two-stage protocol that allows for the acquisition of GATA1+ megakaryocyte / erythroid progenitor cells in a short culture period of 4 days, and for the acquisition of CD71+CD235+CD34- erythroid progenitor cells in a short culture period of 9 days. Thus, the method of the present disclosure can be used to obtain progenitor cells of both megakaryocyte / platelet and erythroid lineages, and can also be used to obtain more differentiated progenitor cells in the erythroid lineage process that can be further differentiated into erythrocytes.

[0009] The culture medium of the present disclosure includes small molecule agents that either agonize or antagonize specific signaling pathways in stem cells, resulting in the promotion of differentiation of HSCs along the erythroid lineage, leading to the expression of biomarkers associated with erythroid cells. The method of the present disclosure has the advantage of significantly shortening the time required to obtain erythroid progenitor cells and reducing associated costs by using less expensive reagents compared to earlier protocols. For example, the culture medium of the present disclosure does not require the use of stem cell factor (SCF), an expensive reagent. Furthermore, the use of small molecule agents in the culture medium allows for tight control of culture components.

[0010] Thus, in one aspect, the present disclosure relates to a method for producing human GATA1+ megakaryocytic / erythroid progenitor (MEP) cells, the method comprising the steps of: culturing human CD34+ hematopoietic stem cells (HSCs) in a culture medium comprising an IL3R pathway agonist, a TGFβ pathway agonist, an AHR pathway antagonist, a RET pathway antagonist, and an AKT pathway antagonist from day 0 to day 4 to obtain human GATA1+ MEP cells.

[0011] In one embodiment, human GATA1+ MEP cells are further cultured in a culture medium containing an AHR antagonist, an iron source, an EPOR agonist, an AMPK agonist, and a lipid source on days 4 to 9 to obtain human CD71+CD235+CD34- erythroid progenitor cells.

[0012] In one embodiment, the HSCs are derived from umbilical cord blood. In one embodiment, the HSCs are derived from bone marrow. In one embodiment, the HSCs are derived from peripheral blood.

[0013] In one embodiment, the IL3R pathway agonist is IL-3. In one embodiment, IL-3 is present in the culture medium at a concentration in the range of 5-15 ng / ml. In one embodiment, IL-3 is present in the culture medium at a concentration of 10 ng / ml.

[0014] In one embodiment, the TGFβ pathway agonist is selected from the group consisting of alantolactone, activin A, TFGB1, nodal, and combinations thereof. In one embodiment, the TGFβ pathway agonist is present in the culture medium at a concentration in the range of 500-1000 nM. In one embodiment, the TGFβ pathway agonist is alantolactone, which is present in the culture medium at a concentration of 750 nM.

[0015] In one embodiment, the AHR pathway antagonist is selected from the group consisting of SR1, GNF351, AHR antagonist 5 hemimaleate, AHR antagonist 1, PDM2, BAY 2416964, CH-223191, AHR antagonist 2, AHR antagonist 4, and combinations thereof. In one embodiment, the AHR pathway antagonist is present in the culture medium at a concentration in the range of 500-1000 nM. In one embodiment, the AHR pathway antagonist is SR1, which is present in the culture medium at a concentration of 750 nM.

[0016] In one embodiment, the RET pathway antagonist is selected from the group consisting of RETki, Lenvatinib, Regorafenib, Pralsetinib, Selpertinib, Lenvatinib Mesylate, RET-IN-4, RPI-1, JNJ38158471, Amuvatinib, TG101209, Regorafenib Hydrochloride, Ilorasertib Hydrochloride, AST487, PF477736, BBT594, AD80, GSK3179106, SPP86, RET-IN-3, WF-47-JS03, RET V804M-IN-1, Trans-Pralsetinib, PZ1, Regorafenib D3, RET-IN-1, ML786 Dihydrochloride, WHI-P180 Hydrochloride, and combinations thereof. In one embodiment, the RET pathway antagonist is present in the culture medium at a concentration in the range of 500-1000 nM. In one embodiment, the RET pathway agonist is a RETki, which is present in the culture medium at a concentration of 750 nM.

[0017] In one embodiment, the AKT pathway antagonist is MK2206, GSK690693, Perifosine (KRX-0401), Ipatasertib (GDC-0068), Capivasertib (AZD5363), PF-04691502, AT 7867, Triciribine (NSC154020), ARQ751, Milansertib (ab235550), Borussertib, Cerisertib, Akti1 / 2, CCT128930, A 674563, PHT 427, Miltefosine, AT 13148, ML 9, BAY 1125976, Oridonin, TIC10, Pectolinarin, Acti IV, 10-DEBC, API-1, SC 66, FPA 124, API-2, urolithin A, and combinations thereof. In one embodiment, the AKT pathway antagonist is present in the culture medium at a concentration in the range of 50 to 150 nM. In one embodiment, the AKT pathway antagonist is MK2206, which is present in the culture medium at a concentration of 100 nM.

[0018] In one embodiment, the iron source is selected from the group consisting of holotransferrin, FeIII_EDTA, Optferrin, FeSO4, ferrous nitrate, lactoferrin, ferritin, and combinations thereof. In one embodiment, the iron source is present in the culture medium at a concentration in the range of 150-250 ug / ml. In one embodiment, the iron source is holotransferrin, which is present in the culture medium at a concentration of 200 ug / ml.

[0019] In one embodiment, the EPOR pathway agonist is selected from the group consisting of EPO, EPO analogs, and combinations thereof. In one embodiment, the EPOR pathway agonist is EPO. In one embodiment, the EPOR pathway agonist is EPO, which is present in the culture medium at a concentration of 2 U / ml.

[0020] In one embodiment, the AMPK pathway agonist is selected from the group consisting of AICAR, metformin, BC1618, malvidin-3-O-arabinoside chloride, A-769662, MK8722, bempedoic acid, AICAR phosphate, phenformin hydrochloride, EX229, gingerol, cadinol B, PF06409577, flufenamic acid, GSK621, urolithin B, MK3903, chitosan oligosaccharide, palmitoelaidic acid, O-304, amarogentin, 7-methoxyisoflavone, EB-3D, buformin hydrochloride, platycodin D, ZLN024 hydrochloride, danthron, Ampkinone, ginkgolide C. C), Gomisin J, Demethylenebernerine, ASP4132, IM156, Vacarin, MOTS-c (human) acetate, Kahweol, AMPK activator 4, Malein, Euphorbia steroid, Simirasemoside C, Metformin D6 hydrochloride, MT6378, RSVA405, Nepodin, 3α-hydroxymogrol, AMPK activator 1, YLF-466D, Buformin, IQZ23, Galesin hydrochloride, Karanjin, COH-SR4, HL271, ZLN024, EB-3D, and combinations thereof. In one embodiment, the AMPK pathway agonist is present in the culture medium at a concentration in the range of 50-150 uM. In one embodiment, the AMPK pathway agonist is AICAR, which is present in the culture medium at a concentration of 100 uM.

[0021] In one embodiment, the lipid source is selected from the group consisting of Albumax, free fatty acid, lysophosphatidylcholine triacylglyceride, phosphatidylcholine, phosphatidic acid, cholesterol, sphingomyelin, knockout serum replacement, Lipid Mixture 1™, Chemically Defined Lipid Concentrate™, bovine serum albumin, human serum albumin, and combinations thereof.In one embodiment, the lipid source is Albumax.In one embodiment, the lipid source is Albumax, which is present in the culture medium at a concentration of 0.5%.

[0022] In another aspect, the present disclosure relates to a method of producing human CD71+CD235+CD34- erythroid progenitor cells, the method comprising the steps of: (a) culturing human CD34+ hematopoietic stem cells (HSCs) in a culture medium containing an IL3R pathway agonist, a TGFβ pathway agonist, an AHR pathway antagonist, a RET pathway antagonist, and an AKT pathway antagonist on days 0 to 4 to obtain human GATA1+ MEP cells; and (b) further culturing the human GATA1+ MEP cells in a culture medium containing an AHR antagonist, an iron source, an EPOR agonist, an AMPK agonist, and a lipid source on days 4 to 9 to obtain human CD71+CD235+CD34- erythroid progenitor cells.

[0023] Non-limiting exemplary reagents and exemplary concentrations include those listed above. In one embodiment, in step (a), the IL3R pathway agonist is IL-3, the TGFβ pathway antagonist is alantolactone, the AHR pathway antagonist is SR1, the RET pathway antagonist is RETki, and the AKT pathway antagonist is MK2206. In one embodiment, in step (a), IL-3 is present in the culture medium at a concentration of 10 ng / ml, alantolactone is present in the culture medium at a concentration of 750 nM, SR1 is present in the culture medium at a concentration of 750 nM, RETki is present in the culture medium at a concentration of 750 nM, and MK2206 is present in the culture medium at a concentration of 100 nM.

[0024] In one embodiment, in step (b), the AHR pathway antagonist is SR1, the iron source is holotransferrin, the EPOR pathway agonist is EPO, the AMPK pathway agonist is AICAR, and the lipid source is Albumax.In one embodiment, in step (b), SR1 is present in the culture medium at a concentration of 750 nM, holotransferrin is present in the culture medium at a concentration of 200 ug / ml, EPO is present in the culture medium at a concentration of 2 U / ml, AICAR is present in the culture medium at a concentration of 100 uM, and Albumax is present in the culture at a concentration of 0.5%.

[0025] In another aspect, the present disclosure relates to the culture medium for producing human erythroid progenitor cells.In one embodiment, the present disclosure provides the culture medium for obtaining human GATA1+ megakaryocyte / erythroid progenitor (MEP) cells, the culture medium comprises IL3R pathway agonist, TGFβ pathway agonist, AHR pathway antagonist, RET pathway antagonist and AKT pathway antagonist.In one embodiment, the present disclosure provides the culture medium for obtaining human CD71+CD235+CD34- erythroid progenitor cells, the culture medium comprises AHR antagonist, iron source, EPOR agonist, AMPK agonist and lipid source.

[0026] In another aspect, the present disclosure relates to an isolated cell culture of human erythroid progenitor cells.In one embodiment, the present disclosure provides an isolated cell culture of human GATA1+ megakaryocyte / erythroid progenitor (MEP) cells, the culture comprises human GATA1+ MEP cells cultured in a culture medium comprising an IL3R pathway agonist, a TGFβ pathway agonist, an AHR pathway antagonist, a RET pathway antagonist, and an AKT pathway antagonist.In one embodiment, the present disclosure provides an isolated cell culture of human CD71+ CD235+ CD34- erythroid progenitor cells, the culture comprises human CD71+ CD235+ CD34- erythroid progenitor cells cultured in a culture medium comprising an AHR antagonist, an iron source, an EPOR agonist, an AMPK agonist, and a lipid source.

[0027] Also provided is the human erythroid progenitor cell produced by the method of the present disclosure.In one embodiment, the present disclosure relates to the human GATA1+ megakaryocyte / erythroid progenitor (MEP) cell produced by the method of the present disclosure.In one embodiment, the present disclosure relates to the human CD71+CD235+CD34- human erythroid progenitor cell produced by the method of the present disclosure.

[0028] Other features and advantages of the invention will become apparent from the following detailed description, and from the claims. [Brief description of the drawings]

[0029] [Figure 1] Figure 1 shows the results from the HD-DoE model of an 8-factor experiment optimized for maximum expression of GATA1. The top of the model shows the predicted expression levels of 53 preselected genes when optimized for GATA1. The bottom of the model shows the effectors tested in this model and their contribution to maximum expression of GATA1. The "Value" column refers to the concentration of each effector that is required to mimic the model. [Diagram 2] Figure 2 shows the results from the HD-DoE model of a six-factor experiment optimized for maximum expression of GATA1. The top of the model shows the predicted expression levels of 53 preselected genes when optimized for GATA1. The bottom of the model shows the effectors tested in this model and their contribution to maximum expression of GATA1. The "Value" column indicates the concentration of each effector required to mimic the model. [Diagram 3]Figure 3 shows the results from the HD-DoE model of the 12-factor experiment optimized for maximum expression of HBA1. The top of the model shows the predicted expression levels of 53 preselected genes when optimized for HBA1. The bottom of the model shows the effectors tested in this model and their contribution to maximum expression of HBA1. The "Value" column indicates the concentration of each effector required to mimic the model. [Figure 4A] Figure 4A-4B show the dynamic profile of expression levels of GATA1, GATA2, CD36 and TFRC genes against the concentration of one verified effector tested on MEP cells. Figure 4A shows the expression level of the gene of interest in the presence of all three final effectors. Figure 4B shows the expression level of the gene of interest in the absence of one of the final effectors but the presence of the others. The positive effect of the effector on the expression of the gene and their factorial contribution are shown by the slope of the plot for each effector. [Figure 4B] See legend to Figure 4A. [Figure 5A] Figure 5A-5B show the dynamic profile of expression levels of GATA1, HBA1, GYPA and TFRC genes against the concentration of one validated effector tested for conversion to erythroid cells. Figure 5A shows the expression level of the gene of interest in the presence of all six final effectors. Figure 5B shows the expression level of the gene of interest in the absence of one of the final effectors but the presence of the others. The positive effect of the effector on the expression of the gene and their factorial contribution are shown by the slope of the plot for each effector. [Figure 5B] See legend to Figure 5A. [Figure 6]Figures 6A-6B show flow cytometry analysis of cord blood CD34+ cells grown for 4 or 5 days in either Stage 1 medium or literature medium. Figure 6A shows results for cells stained with antibodies against CD71, CD235 (glycogen), and FVS700, a viability marker, to exclude dead cells from the analysis. Figure 6B shows the mean fluorescence intensity (MFI) of CD71+ cells grown in Stage 1 medium and in culture medium on days 4 and 5. [Figure 7A] 7A-7B show the results of flow cytometry analysis of cord blood CD34+ cells that were grown for 4 or 5 days in Stage 1 medium (dark grey) or literature medium (light grey). Results are shown for cells stained with antibodies against CD71, CD34, CD38, CD123, CD45RA, CD41, and FVS700, as well as viability markers to exclude dead cells from the analysis. [Figure 7B] See legend to Figure 7A. [Figure 8A] Figures 8A-8C show flow cytometry analysis of cord blood CD34+ cells grown for 4 days in either Stage 1 medium or literature medium, followed by growth for 3, 5, or 7 days in either Stage 2 medium or literature medium. Cells were stained with antibodies against CD71, CD235 (glycophorin A and B), and FVS700, a viability marker, to exclude dead cells from the analysis. Figure 8A shows the results of 3 days of culture in Stage 2 medium. Figure 8B shows the results of 5 days of culture in Stage 2 medium. Figure 8C shows the results of 7 days of culture in Stage 2 medium. [Figure 8B] See legend to Figure 8A. [Figure 8C] See legend to Figure 8A. [Figure 9A]9A-9C show flow cytometry analysis of cord blood CD34+ cells grown for 4 days in either Stage 1 medium or literature medium, followed by growth for 3, 5, or 7 days in either Stage 2 medium or literature medium. Cells were stained for DNA using DRAQ5. FIG. 9A shows the results of 3 days of culture in Stage 2 medium. FIG. 9B shows the results of 5 days of culture in Stage 2 medium. FIG. 9C shows the results of 7 days of culture in Stage 2 medium. [Figure 9B] See legend to Figure 9A. [Figure 9C] See legend to Figure 9A. [Figure 10] Figure 10 shows the results of flow cytometry analysis of umbilical cord blood CD34+ cells, which were grown in stage 1 medium for 4 days, followed by growth in stage 2 medium with two different basal media for 5 days. Stemline 2 medium was compared to the exemplary basal media. Cells were stained with antibodies against CD71, CD235 (glycophorin A and B), and FVS700, a viability marker, to exclude dead cells from the analysis. The number of cells in the culture was evaluated after growing cells in stage 2 medium for 5 days. [Figure 11] 11A-11B show contour plots depicting the expression of HBA at various concentrations of cholesterol supplement and holo-transferrin (FIG. 11A) and at various concentrations of cholesterol supplement and EPO (FIG. 11B). The dark areas at the top of the plot indicate maximum expression of HBA, while the dark areas at the bottom indicate minimum expression of HBA. This analysis shows that adding cholesterol supplement and high concentrations of EPO and holo-transferrin are optimal for maximizing expression of HBA in the system. [Figure 12]Figure 12 shows the results from the HD-DoE model of a 12-factor experiment optimized for maximum expression of HBG2, an erythroid marker. The top of the model shows the predicted expression levels of 53 preselected genes when optimized for HBG2. The bottom of the model shows the effectors tested in the model and their contribution to maximum expression of HBG2. The "Value" column refers to the concentration of each effector required to mimic the model. This model shows that HSCs grown in Stage 1 medium to generate MEP cells give rise to cells with the potential to differentiate into erythroid lineages. [Figure 13] Figure 13 shows the results from the HD-DoE model of an 8-factor experiment optimized for maximum expression of PF4, a megakaryocyte / platelet marker. The top of the model shows the predicted expression levels of 53 preselected genes when optimized for PF4. The bottom of the model shows the effectors tested in the model and their contribution to maximum expression of PF4. The "Value" column refers to the concentration of each effector required to mimic the model. This model shows that HSCs grown in Stage 1 medium to generate MEP cells give rise to cells that have the potential to differentiate into platelet lineage. [Figure 14] FIG. 14 is a schematic diagram of a representative culture method of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] Detailed Description of the Invention Herein, methodologies and compositions are described that allow the generation of human erythroid progenitor cells from human CD34+ hematopoietic stem cells (HSCs) under chemically defined culture conditions using a small molecule-based approach. As described in Example 1, a High-Dimensional Design of Experiments (HD-DoE) approach was used to simultaneously test multiple inputs of a process (e.g., small molecule agonists or antagonists) against an output response, such as gene expression. These experiments allowed the identification of a chemically defined culture medium that contains agonists and / or antagonists of specific signaling pathways, sufficient to generate erythroid progenitor cells from HSCs in a very short time in a two-stage protocol. In the first stage of the protocol, GATA1+ megakaryocyte / erythroid progenitor (MEP) cells are generated from CD34+ HSCs. In the second stage of the protocol, CD71+CD235+CD34- erythroid progenitor cells are generated from GATA1+ MEP cells. The optimized two-stage culture medium was further validated by factor lethality analysis, which investigated the effect of removing individual agonist or antagonist agents, as described in Example 2. The phenotype of cells generated by the differentiation protocol was further confirmed by flow cytometry analysis, as described in Example 3. Furthermore, the differentiation potential of megakaryocyte / erythroid progenitor (MEP) cells generated by the method of the present disclosure was investigated in Example 4. A representative culture method of the present disclosure is shown as a schematic diagram in FIG. 14.

[0031] Various aspects of the invention are described in greater detail in the following subsections.

[0032] I. cell The starting cells used in the culture of the present disclosure are human CD34+ hematopoietic stem cells.As used herein, the term "hematopoietic stem cell" (abbreviated as HSC) refers to stem cells that have the ability to differentiate into a wide variety of different types of hematopoietic cells.CD34 is a transmembrane phosphorylated glycoprotein that has been established in the art as a surface marker for HSC.Human HSC can be easily obtained from available sources, including human umbilical cord blood, adult bone marrow, and peripheral blood.HSC includes both long-term HSC (LT-HSC) and short-term HSC (ST-HSC).

[0033] Long-term HSCs (LT-HSCs) are HSCs found in bone marrow or umbilical cord blood that can self-renew to maintain the stem cell pool through a process of asymmetric cell division, or can differentiate into short-term HSCs (ST-HSCs) or into lineage-restricted progenitor cells that undergo active proliferation and differentiation to produce terminally differentiated cells in the blood lineage. LT-HSCs are thought to be enriched in the Lin-CD34+CD38-CD45RA-CD90+ cell fraction. LT-HSCs are quiescent and slowly dividing cells in culture, taking up to 80 hours to undergo their first cell division (Cheung and Rando (2013) Nat. Rev. Mol. Cell Biol. 14:329-340). In contrast, short-term HSCs (ST-HSCs) are by definition limited self-renewal capacity and are commonly described to undergo lympho- and hematopoietic generation for 4-12 weeks before senescence.

[0034] In one embodiment, the HSC expresses CD34 (CD34+). In one embodiment, the HSC does not express Lineage markers (Lin-). In one embodiment, the HSC does not express CD38 (CD38-). In one embodiment, the HSC does not express CD45RA (CD45RA-). In one embodiment, the HSC expresses CD90 (CD90+). In one embodiment, the HSC is a Lin-CD34+CD38-CD45RA-CD90+ cell.

[0035] In certain embodiments, the HSCs express one or more genes associated with the HSC phenotype (also referred to herein as HSC-associated genetic markers), non-limiting examples of which include CHRBP, Mecom, Meg3, HOPX, LMO2, CD34, TAL1, and GATA2.

[0036] II. Culture medium components The disclosed method for generating human erythroid progenitor cells from CD34+ HSCs comprises culturing human CD34+ HSCs in a culture medium comprising a specific agonist and / or antagonist for a cell receptor and / or a signaling pathway. In certain embodiments, the culture medium is not supplemented with exogenous serum, and / or the culture medium is not supplemented with exogenous bovine serum albumin, and / or the culture medium lacks stem cell factor (SCF) (i.e., the medium does not contain SCF).

[0037] In one embodiment, the present disclosure provides a culture medium for obtaining human GATA1+ megakaryocyte / erythroid progenitor (MEP) cells, the culture medium comprises an IL3R pathway agonist, a TGFβ pathway agonist, an AHR pathway antagonist, a RET pathway antagonist, and an AKT pathway antagonist.In one embodiment, the present disclosure provides a culture medium for obtaining human CD71+CD235+CD34- erythroid progenitor cells, the culture medium comprises an AHR antagonist, an iron source, an EPOR agonist, an AMPK agonist, and a lipid source.

[0038] As described in Example 1, the culture medium containing an IL3R pathway agonist, a TGFβ pathway agonist, an AHR pathway antagonist, a RET pathway antagonist, and an AKT pathway antagonist was sufficient to generate GATA1+ MEP cells from CD34+ HSCs in as short a period as 4 days. Furthermore, further culture in a culture medium containing an AHR antagonist, an iron source, an EPOR agonist, an AMPK agonist, and a lipid source for another 5 days was sufficient to generate CD71+CD235+CD34- erythroid progenitor cells from GATA1+ MEP cells.

[0039] As used herein, the "agonist" of a cell receptor or a signal transduction pathway is intended to refer to an agent that stimulates (activates) a cell receptor or a signal transduction pathway. The stimulation of a cell signal transduction pathway can be initiated outside the cell, for example, by using an agonist that activates a cell surface receptor involved in the signal transduction pathway (for example, the agonist can be a ligand of the receptor). Additionally or alternatively, the stimulation of a cell signal transduction can be initiated inside the cell, for example, by using a small molecule agonist that interacts with a component of the signal transduction pathway inside the cell.

[0040] As used herein, the "antagonist" of cell signaling pathway is intended to refer to an agent that inhibits (downregulates) cell signaling pathway.The inhibition of cell signaling pathway can be initiated outside the cell, for example, by using an antagonist that blocks the cell surface receptor involved in the signaling pathway.In addition or alternatively, the inhibition of cell signaling can be initiated inside the cell, for example, by using a small molecule antagonist that interacts with the component of the signaling pathway inside the cell.

[0041] IL3R pathway agonist, TGFβ pathway agonist, AHR pathway antagonist, RET pathway antagonist, AKT pathway antagonist, iron source, EPOR agonist, AMPK agonist and lipid source are known in the art and commercially available.They are used in culture medium at effective concentrations to achieve desired outcome, where desired outcome is, for example, the production of erythroid progenitor cells expressing marker of interest.The non-limiting examples of suitable agonist and antagonist agents and effective concentration ranges are further described below.

[0042] Agonists of the IL3R pathway include agents, molecules, compounds, or substances that can stimulate (activate) the IL3R signaling pathway. In one embodiment, the IL3R pathway agonist is IL3 or an IL3R binding analog thereof. In another embodiment, the IL3R pathway agonist is IL-3. In one embodiment, the IL3R pathway agonist is IL-3, which is present in the medium at a concentration in the range of 5-15 ng / ml, 6-14 ng / ml, 7-13 ng / ml, or 8-12 ng / ml. In one embodiment, the IL3R pathway agonist is IL-3, which is present in the medium at a concentration of 10 ng / ml.

[0043] Agonists of the TGFβ pathway include agents, molecules, compounds, or substances capable of stimulating (activating) the TGFβ signaling pathway. In one embodiment, the TGFβ pathway agonist is selected from the group consisting of alantolactone, activin A, TGFB1, nodal, and combinations thereof. In one embodiment, the TGFβ pathway agonist is activin A. In another embodiment, the TGFβ pathway agonist is alantolactone. In one embodiment, the TGFβ pathway agonist is alantolactone, which is present in the medium at a concentration in the range of 500-1000 nM, in the range of 600-900 nM, or in the range of 700-800 nM. In one embodiment, the TGFβ pathway agonist is alantolactone, which is present in the medium at a concentration of 750 nM.

[0044] Antagonists of the AHR (Aromatic Hydrocarbon Receptor) pathway include agents, molecules, compounds, or substances capable of inhibiting (downregulating) the AHR signaling pathway. In one embodiment, the AHR pathway antagonist is selected from the group consisting of SR1, GNF351, AHR antagonist 5 hemimaleate, AHR antagonist 1, PDM2, BAY 2416964, CH-223191, AHR antagonist 2, AHR antagonist 4, and combinations thereof. In one embodiment, the AHR pathway antagonist is present in the culture medium at a concentration within the range of 500-1000 nM, within the range of 600-900 nM, or within the range of 700-800 nM. In one embodiment, the AHR pathway antagonist is SR1, which is present in the culture medium at a concentration in the range of 500-1000 nM, in the range of 600-900 nM, or in the range of 700-800 nM. In one embodiment, the AHR pathway antagonist is SR1, which is present in the culture medium at a concentration of 750 nM.

[0045] Antagonists of the RET (rearranged during transfection) pathway include agents, molecules, compounds, or substances capable of inhibiting (downregulating) the RET signaling pathway. In one embodiment, the RET pathway antagonist is selected from the group consisting of RETki, Lenvatinib, Regorafenib, Pralsetinib, Selpertinib, Lenvatinib Mesylate, RET-IN-4, RPI-1, JNJ38158471, Amuvatinib, TG101209, Regorafenib Hydrochloride, Ilorasertib Hydrochloride, AST487, PF477736, BBT594, AD80, GSK3179106, SPP86, RET-IN-3, WF-47-JS03, RET V804M-IN-1, Trans-Pralsetinib, PZ1, Regorafenib D3, RET-IN-1, ML786 Dihydrochloride, WHI-P180 Hydrochloride, and combinations thereof. In one embodiment, the RET pathway antagonist is present in the culture medium at a concentration in the range of 500-1000 nM, in the range of 600-900 nM, or in the range of 700-800 nM. In one embodiment, the RET pathway antagonist is a RETki, which is present in the culture medium at a concentration in the range of 500-1000 nM, in the range of 600-900 nM, or in the range of 700-800 nM. In one embodiment, the RET pathway antagonist is a RETki, which is present in the culture medium at a concentration of 750 nM.

[0046] Antagonists of the AKT pathway include agents, molecules, compounds, or substances capable of inhibiting (downregulating) the AKT signaling pathway. In one embodiment, the AKT pathway antagonist is MK2206, GSK690693, Perifosine (KRX-0401), Ipatasertib (GDC-0068), Capivasertib (AZD5363), PF-04691502, AT 7867, Triciribine (NSC154020), ARQ751, Milansertib (ab235550), Borsertib, Serisertib, Akti1 / 2, CCT128930, A 674563, PHT 427, Miltefosine, AT 13148, ML 9, BAY 1125976, Oridonin, TIC10, Pectolinarin, Acti IV, 10-DEBC, API-1, SC 66, FPA 124, API-2, urolithin A, and combinations thereof. In one embodiment, the AKT pathway antagonist is present in the culture medium at a concentration in the range of 500-1000 nM, in the range of 600-900 nM, or in the range of 700-800 nM. In one embodiment, the AKT pathway antagonist is MK2206, which is present in the culture medium at a concentration in the range of 500-1000 nM, in the range of 600-900 nM, or in the range of 700-800 nM. In one embodiment, the AKT pathway antagonist is MK2206, which is present in the culture medium at a concentration of 750 nM.

[0047] Non-limiting exemplary embodiments of the iron source include holotransferrin, FeIII_EDTA, Optferrin, FeSO4, ferrous nitrate, and combinations thereof. In one embodiment, the iron source is present in the culture medium at a concentration in the range of 100-300 ug / ml, in the range of 150-250 ug / ml, or in the range of 175-225 ug / ml. In one embodiment, the iron source is holotransferrin, which is present in the culture medium at a concentration in the range of 100-300 ug / ml, in the range of 150-250 ug / ml, or in the range of 175-225 ug / ml. In one embodiment, the iron source is holotransferrin, which is present in the culture medium at a concentration of 200 ug / ml.

[0048] Agonists of the EPOR pathway include agents, molecules, compounds, or substances that can stimulate (activate) the erythropoietin receptor (EPOR) signaling pathway. In one embodiment, the EPOR pathway agonist is EPO or an EPOR-binding analog thereof. In another embodiment, the EPOR pathway agonist is EPO. In one embodiment, the EPOR pathway agonist is EPO, which is present in the medium at a concentration in the range of 1-3 U / ml, in the range of 1.5-2.5 U / ml, or in the range of 1.75-2.25 U / ml. In one embodiment, the EPOR pathway agonist is EPO, which is present in the medium at a concentration of 2 U / ml.

[0049] Agonists of the AMPK (AMP-activated protein kinase) pathway include agents, molecules, compounds, or substances that can stimulate (activate) the AMPK signaling pathway.In one embodiment, the AMPK pathway agonist is AICAR, metformin, BC1618, malvidin-3-O-arabinoside chloride, A-769662, MK8722, bempedoic acid, AICAR phosphate, phenformin hydrochloride, EX229, gingerol, casinol B, PF06409577, flufenamic acid, GSK621, urolithin B, MK3903, chitosan oligosaccharide, palmitoelaidic acid, O-304, amarogentin, 7-methoxyisoflavone, EB-3D, buformin hydrochloride, platycodin D, ZLN024 hydrochloride, danthron, anthracene, alpha-amylase ... The agonist is selected from the group consisting of pukhinone, ginkgolide C, gomisin J, demethylenebernerin, ASP4132, IM156, baccarin, MOTS-c (human) acetate, kahweol, AMPK activator 4, malein, euphorbia steroid, simirasemoside C, metformin D6 hydrochloride, MT6378, RSVA405, nepodin, 3α-hydroxymogrol, AMPK activator 1, YLF-466D, buformin, IQZ23, galesin hydrochloride, karanjin, COH-SR4, HL271, ZLN024, EB-3D, and combinations thereof. In one embodiment, the AMPK pathway agonist is present in the culture medium at a concentration in the range of 50-250 uM, in the range of 50-150 uM, or in the range of 75-125 uM. In one embodiment, the AMP pathway agonist is AICAR, which is present in the culture medium at a concentration in the range of 50-250 uM, in the range of 50-150 uM, or in the range of 75-125 uM. In one embodiment, the AMP pathway agonist is AICAR, which is present in the culture medium at a concentration of 100 uM.

[0050] Non-limiting exemplary embodiments of lipid sources include Albumax, free fatty acids, lysophosphatidylcholine triacylglycerides, phosphatidylcholine, phosphatidic acid, cholesterol, sphingomyelin, knockout serum replacement, Lipid Mixture 1™ (Sigma-Aldrich), Chemically Defined Lipid Concentrate™ (ThermoFisher Scientific), and combinations thereof. In one embodiment, the lipid source is Albumax. In one embodiment, the lipid source is Albumax, which is present in the culture medium at a concentration within the range of 0.1-1.0%, within the range of 0.25-0.75%, or within the range of 0.4-0.6%. In one embodiment, the lipid source is Albumax, which is present in the culture medium at a concentration of 0.5%.

[0051] III. Culture conditions The disclosed method of generating human erythroid progenitor cells from CD34+ HSC utilizes standard culture conditions for cell culture that are established in the art in combination with the chemically defined and optimized culture medium described in subsection II above. For example, cells can be cultured at 37 degrees and under 5% O2 and 5% CO2 conditions. A basal medium can be used as a starting medium to which supplement agents can be added. For example, in one embodiment, commercially available Stemline® II Hematopoietic Stem Cell Expansion Medium (Sigma-Aldrich) can be used as the basal medium. In another embodiment, commercially available StemSpan™ SFEM II Medium (STEMCELL Technologies) can be used as the basal medium. Other non-limiting examples of suitable basal media include X-VIVO™ 15 serum-free hematopoietic cell medium (Lonza Bioscience), StemMACS™ HSC expansion medium (Miltenyi Biotec), and StemPro™-34 SFM (ThermoFisher Scientific; Catalog No. 10639011). In addition, those skilled in the art can develop suitable serum-free basal media using reagents established in the art. Cells can be cultured in standard culture vessels or culture plates, such as culture dishes, culture flasks, or 96-well plates.

[0052] The starting cell CD34+ HSC can be obtained by methods established in the art. Sources of human CD34+ HSC include umbilical cord blood, peripheral blood and bone marrow. CD34+ HSC can be obtained, for example, by standard magnetic enrichment.

[0053] In various embodiments of the method of the present disclosure, the starting cell CD34+ HSC is cultured in a specific culture medium for a sufficient time to produce a cell that expresses one or more of the biomarkers of the product cell of interest.The starting cell HSC expresses the CD34 marker.Non-limiting examples of additional HSC-associated gene markers include CHRBP, Mecom, Meg3, HOPX, LMO2, CD34, TAL1, and GATA2.

[0054] In some embodiments, CD34+ HSCs are cultured in stage 1 medium for a sufficient time to produce megakaryocytic / erythroid progenitor (MEP) cells, which can be identified based on the expression of one or more MEP-associated biomarkers. Non-limiting examples of MEP-associated biomarkers include GATA1, TFRC, TAL1, and GATA2. In various embodiments, MEP cells can express at least one, at least two, at least three, or at least four MEP-associated biomarkers. In one embodiment, the cells are cultured for a sufficient time to increase the expression level of at least one MEP-associated biomarker by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to the starting cell population. The expression level of gene markers in the cultured cells can be measured by techniques available in the art (e.g., RNAseq analysis). In one embodiment, the MEP cells are GATA1+. In one embodiment, CD34+ HSCs are cultured in Stage 1 medium for a sufficient time to generate GATA1+ MEP cells, where less than 10% of the cells in the culture are positive for CD41 and CD235.

[0055] In some embodiments, GATA1+ MEP cells are cultured in stage 2 medium for a sufficient time to produce erythroid lineage-committed progenitor cells, which can be identified based on the expression of one or more erythroid lineage-associated biomarkers. In some embodiments, erythroid lineage-committed progenitor cells are CD71+ and CD235+, and are also CD34-negative (CD34-). Non-limiting examples of additional erythroid lineage-associated biomarkers include HBA1, CD36, TFRC, PRG2, HBB, HBG2, ALAD, ALAS2, CA2, GYPA, GYPB, GATA1, KLF1, and TFRC. In various embodiments, erythroid progenitor cells can express at least one, at least two, at least three, or at least four, at least five, or more erythroid lineage-associated biomarkers. In one embodiment, the cells are cultured for a sufficient time to increase the expression level of at least one erythroid lineage-associated biomarker by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to the starting cell population. The expression level of the genetic marker in the cultured cells can be measured by techniques available in the art (e.g., RNAseq analysis).

[0056] In one embodiment, the cells are cultured in Stage 1 medium from day 0 to day 4 of culture, or for at least 4 days, or for at least 96 hours. In one embodiment, the cells are cultured in Stage 2 medium from day 5 to day 9 of culture, or for at least 5 days (after Stage 1 culture), or for at least 120 hours (after Stage 1 culture).

[0057] Culture medium is typically replaced with fresh medium periodically, for example, in various embodiments, medium is replaced every 24 hours, every 48 hours, or every 72 hours.

[0058] IV. Purpose The disclosed method and composition for producing human erythroid progenitor cells allows these cell populations to be efficiently and stably used in various applications.For example, the disclosed method and composition can be used to study the development and differentiation of erythroid cells, including biological analysis that helps understand diseases and disorders associated with erythroid cells.For example, the erythroid progenitor cells produced using the disclosed method can be further purified using agents that bind to surface markers expressed on the cells according to techniques established in the art.

[0059] In addition, the erythroid progenitor cells of the disclosed method are intended to be used to make blood components for transfusion.For example, the MEP cells of the disclosed method can be further differentiated into platelets, which can be used for transfusion in subjects in need.Similarly, the MEP cells and CD71+CD235+CD34- erythroid progenitor cells can be further differentiated into red blood cells, which can be used for transfusion in subjects in need.Therefore, the disclosed method and composition can also be used for the treatment of various hematopoietic diseases and disorders that require transfusion of platelets and / or RBCs.

[0060] V. composition In other aspects, the disclosure provides compositions related to methods of producing erythroid progenitor cells, the compositions including a culture medium and an isolated cell culture.

[0061] In one aspect, the present disclosure provides a culture medium for obtaining human GATA1+ megakaryocyte / erythroid progenitor (MEP) cells, the culture medium comprises an IL3R pathway agonist, a TGFβ pathway agonist, an AHR pathway antagonist, a RET pathway antagonist, and an AKT pathway antagonist.In another aspect, the present disclosure provides a culture medium for obtaining human CD71+CD235+CD34- erythroid progenitor cells, the culture medium comprises an AHR antagonist, an iron source, an EPOR agonist, an AMPK agonist, and a lipid source.Non-limiting examples of suitable agents and their concentrations include those described in subsection II above.

[0062] In another aspect, the present disclosure provides an isolated cell culture of human GATA1+ megakaryocyte / erythroid progenitor (MEP) cells, the cell culture comprises human GATA1+ MEP cells cultured in a culture medium comprising an IL3R pathway agonist, a TGFβ pathway agonist, an AHR pathway antagonist, a RET pathway antagonist, and an AKT pathway antagonist.In another aspect, the present disclosure provides an isolated cell culture of human CD71+ CD235+ CD34- erythroid progenitor cells, the cell culture comprises human CD71+ CD235+ CD34- erythroid progenitor cells cultured in a culture medium comprising an AHR antagonist, an iron source, an EPOR agonist, an AMPK agonist, and a lipid source.Non-limiting examples of suitable agents and their concentrations include those described in subsection II above.

[0063] In yet another aspect, the present disclosure provides erythroid progenitor cells produced by the method of the present disclosure.As described herein, in one embodiment, the present disclosure provides human GATA1+ megakaryocyte / erythroid progenitor (MEP) cells produced by the method of the present disclosure.As described herein, in one embodiment, the present disclosure provides human CD71+CD235+CD34- human erythroid progenitor cells produced by the method of the present disclosure.

[0064] The present invention is further illustrated by the following examples, which should not be construed as further limiting. The contents of all figures, references, patents, and patent publications cited throughout this application are expressly incorporated herein by reference. EXAMPLES

[0065] Example 1 : Development of a protocol for generating erythroid progenitor cells derived from hematopoietic stem cells A two-stage recipe for generating erythroid progenitor cells has been developed that can induce human hematopoietic stem cells into progenitor cells expressing CD71 and CD235 after 9 days in culture. These cells can be further differentiated into enucleated erythrocytes.

[0066] This example utilizes high-dimensional experimental design (HD-DoE) as previously described in Bukys et al. (2020) Iscience 23:101346. The method utilizes computational design geometry to simultaneously test multiple inputs of a process and provides deep spatial mathematical modeling of effectors / responses. The method allows for the discovery of combinatorial signaling inputs that control complex processes, such as the process of cell differentiation. The method allows for the testing of multiple plausible important parameters in a process as they affect the output response, such as gene expression. Since gene expression provides a distinct phenotypic characteristic, such as for human cells, the method can be applied to identify and understand which signaling pathways control cell fate. In this example, the HD-DOE method was applied to find conditions for inducing genes that express erythroid progenitors directly from the pluripotent stem cell stage.

[0067] To develop the formulations for each stage, the effects on the expression of two sets of 53 preselected genes after 3 days of treatment with agonists and antagonists of multiple signaling pathways (referred to herein as effectors) were tested and modeled. These effectors are small molecules or proteins that are commonly used in the process of stepwise differentiation of stem cells to specific fates. The selection of effectors was based on a combination of current literature on induction of red blood cells (RBCs) and differentiation of HSCs into hematopoietic progenitors, and available data related to the control of cell fates of other cell types.

[0068] Stage 1 Formulation for Megakaryocyte / Erythroid Progenitors A formula was developed to generate progenitor cells expressing GATA1 with bipotentiality for megakaryocyte and erythroid lineages, which induces human hematopoietic stem cells (HSCs) into progenitor cells expressing CD34 and CD71, with less than 10% of the cells being positive for downstream committed lineage markers CD41 and CD235 (megakaryocyte and erythroid lineage markers, respectively). These bipotential progenitor cells expressing GATA1 can further differentiate into mature platelets and into mature erythrocytes when further cell fate-inducing molecules and signals are applied. Another name for bipotential progenitor cells expressing GATA1 is megakaryocyte / erythroid progenitor (MEP) cells, and the formula for these cells is referred to herein as the formula for stage 1.

[0069] To test effectors, experiments with at least eight different factors were designed that could evaluate the response of cells to various combinations of effectors in a range of concentrations. To analyze the model, we focused on the expression of genes expressed in megakaryocyte / erythroid progenitor cells, such as GATA1, TFRC, TAL1, and GATA2, among others. GATA1 null mice die on embryonic day 10 due to anemia (Pevny et al. (1991) Nature 349:257-260). GATA1 is also required for the maturation of other blood lineages, such as megakaryocytes, eosinophils, and mast cells (Dore and Crispino (2011) Blood 118:231-239). Single-cell studies of primary human CD34 cells have shown that GATA1 is low expressed in common myeloid progenitor cells and high expressed in MEP cells. In addition, Tal1 is also required for blood generation during the embryonic process (Shivdasani et al. (1995) Nature 373:432-434). Deletion of GATA2 in mice causes severe anemia and death on embryonic day 10 (Tsai et al. (1994) Nature 371:221-226). GATA2 is also involved in megakaryocyte development, with its upregulation inhibiting differentiation into erythroid cells and promoting megakaryocytopoiesis (Ikonomi et al. (2000) Exp Hematol. 28:1423-1431). The influence of each effector on the expression level of genes is defined by a parameter called the factor contribution, which is calculated for each effector during the modeling process. All experiments were performed using CD34 isolated from umbilical cord blood. + This was carried out using cell populations.

[0070] To identify the formulation for stage 1 differentiation, cells were grown in medium containing stem cell factor (SCF) for 3 days. Next, 48 different combinations of effectors were prepared mechanically, which were generated using D-optimization experimental design compression. The effector combinations were prepared in basal medium and then added to cells, which were then allowed to differentiate. After 3 days, RNA extraction was performed and gene expression was obtained using quantitative PCR analysis. The data was normalized and modeled using partial least squares regression analysis for the effector design, resulting in gene-specific models that provided descriptions of the ability of effectors to combinatorially and individually control the expression of individual genes after adjustment for maximum Q2, i.e. maximum predictive power. Solutions within the tested space could then be examined to address desirability.

[0071] Optimization for maximum expression of the key regulatory gene, GATA1, resulted in a robust solution. Other genes, such as MKI67, CD36, TFRC, and PRG2, were also predicted to be highly expressed in this solution. These genes further support the plausibility of this condition leading to the production of bipotential progenitor cells expressing GATA1. This model was derived from an initial test of eight factors, including IL3, alantolactone, SR1, RETki, MK2206, rosiglitazone, sc79, and dexamethasone. As shown in Figure 1, five of these effectors: IL3, alantolactone, SR1, RETki, and MK2206, showed a positive impact on the expression of the genes of interest, with factor contributions of 41, 8, 6, 14, and 17, respectively. Within the specifications to achieve 80% maximum expression of GATA1, this complex medium composition has a Cpk value (process capability index) of 0.53, which corresponds to a risk of failure of 3.9%. The present invention, which is a complex set of inputs for MEP cells expressing GATA1, was compared with existing literature and found to be different. Of note, dexamethasone, a commonly used factor for inducing erythropoiesis; it is an agonist of glucocorticoid receptor and an analog of hydrocortisone, was not included and prevented maximum expression of GATA1.

[0072] To test whether EPO, or other commonly used cytokines, are required for the induction of GATA1, we performed an experiment with six factors at a range of concentrations. In this experiment, CD34 cells were thawed and maintained overnight in medium containing 10 ng / mL SCF. The next day, 48 different combinations of effectors were added to the cells, and 5 ng / mL SCF was maintained in all wells. Optimization for maximum expression of the key regulatory gene, GATA1, resulted in a robust solution. In this solution, other genes expressed in megakaryocytes and erythrocytes, such as ITGA2b, ZFPM1, KLF1, and EPOR, were also predicted to be highly expressed. This model was derived from earlier testing of IL6, IL3, SCF, EPO, activin A, and IGFII. As shown in Figure 2, two of these effectors: IL3 and activin A, showed a positive effect on the expression of the gene of interest, with factor contributions of 31 and 33, respectively. EPO is another agent commonly used in the process of initiating erythropoiesis from HSCs, but it is not required for induction of GATA1 and was therefore excluded from our formulation. Activin A, a member of the TGFβ family, was not used in our formulation because alantolactone is also a TGFβ agonist, supports induction of GATA1, and is less expensive.

[0073] In view of the above, representative recipes for stage 1 differentiation are summarized in Table 1 below.

[0074] Table 1. Validated effectors for generating MEP cells from HSCs TIFF2024542842000002.tif46139

[0075] Stage 2 formulation for CD71+CD235+CD34- progenitor cells To create Stage 2 medium, primary CD34+ cells derived from human umbilical cord blood cells were cultured for 5 days in Stage 1 medium (Table 1) that converts hematopoietic stem cells into GATA1 bipotent progenitors (MEP progenitors). These progenitors have the potential to differentiate into erythroid and megakaryocytic lineages. Additional HD-DoE experiments were performed to further induce the differentiation of GATA1 bipotent progenitors. This resulted in an additional gene regulation model that was used to create the differentiation protocol. The basis of this model was a 12-factor HD-DoE experiment that focused on the differentiation of cells into erythroid lineages for an additional 3 days after completion of Stage 1 treatment.

[0076] To test effectors, 96 different combinations of effectors were prepared mechanically, which were generated using D-optimization experimental design compression. Effector combinations were prepared in basal medium and then added to cells, which were then allowed to differentiate. RNA extraction was performed after 3 days, and gene expression was obtained using quantitative PCR analysis. Data was normalized and modeled using partial least squares regression analysis for effector design, resulting in gene-specific models that provided descriptions of the ability of effectors to combinatorially and individually control the expression of individual genes after adjustment for maximum Q2, i.e. maximum predictive power. Solutions within the tested space could then be examined to address desirability.

[0077] Optimization for maximum expression of HBA1 resulted in a robust solution. In this solution, other genes, such as MKI67, TFRC, HBB, HBG2, ALAD, ALAS2, CA2, GYPA, GYPB, GATA1, KLF1, and TFRC, were also predicted to be highly expressed, all of which are highly expressed in erythroid cells, suggesting the commitment of the cells to this lineage. In the same model, CSF1R, TPOR, and MPO were downregulated (genes associated with other hematopoietic lineages). In addition, genes associated with the stem cell stage, CD34, MECOM, and CRHBP, were downregulated, indicating that the cells were differentiated. This model was derived from earlier testing of 12 factors, including: HB-EGF, optiferin, SR1, knockout serum, ibuprofen, GM-CSF, holotransferrin, EPO, eltrombopag, neuregulin 1, THI0019, and AICAR. As shown in Figure 3, five of these effectors: SR1, knockout serum, holo-transferrin, EPO, and AICAR, showed a positive impact on the expression of the gene of interest with factor contributions of 7, 13, 15, 31, and 9, respectively. Within the specifications to achieve 80% maximum expression of HBA1, this complex medium composition had a Cpk value (process capability index) of 0.64, which corresponds to a risk of failure of 2.7%.

[0078] In view of the above, representative recipes for differentiation at stage 2 are summarized in Table 2 below.

[0079] Table 2. Effectors validated in stage 2 formulations for CD71+CD235+CD34- progenitor cells TIFF2024542842000003.tif46170

[0080] Example 2 : Lethality analysis of culture condition factors inducing erythroid progenitor cells derived from hematopoietic stem cells Dynamic profile analysis was used to assess the impact of removing each of the validated factors identified for the Stage 1 and Stage 2 formulations described in Example 1, and comparing the expression levels of the genes of interest in the absence of each final effector but in the presence of the others. This factor lethality analysis revealed the degree of importance of each input effector, since the expression levels of the genes of interest reveal whether the desired outcome is achievable.

[0081] Stage 1 Recipe The final five factors in the stage 1 formula were removed one by one while the other four factors were left in, and the expression levels of GATA2, GATA1, CD36, and TFRC were evaluated compared to when all five factors were present. The results are summarized in Figures 4A-4B. When IL-3 was removed, GATA1 expression decreased from 510 to 240, CD36 expression changed from 260 to 70, GATA2 expression decreased from 2200 to 1400, and TFRC expression dropped from 960 to 580. All changes represent a significant decrease in the expression of genes desirable for MEP progenitors.

[0082] Lack of SR1 caused a decrease in the expression of GATA1, which was a decrease from 510 to 410; SR1 was also noted as an important factor for the expression of TFRC, because removal of SR1 reduced the level of TFRC from 970 to 570. MK2206 is involved in ensuring maximum expression of GATA1, and removal of this AKT inhibitor reduced the level of GATA1 from 510 to 400. Lack of RETki caused a decrease in the expression of GATA1, which was a decrease from 510 to 410. Removal of alantolactone reduced the value of GATA1 from 510 to 460, and its effect on GATA1 expression was weaker than the others.

[0083] Stage 2 Recipe In the stage 2 formula, the final five factors were removed one by one while the other four factors were left in, and the expression levels of GATA1, HBA1, GYPA (CD235), and TFRC were evaluated compared to when all five factors were present. The results are summarized in Figures 5A-5B. When EPO was removed, the value of GATA1 decreased from 1386 to 736, the value of HBA1 changed from 700 to 285, the value of GYPA decreased from 345 to 61, and the value of TFRC dropped from 2943 to 898. All changes represent a significant decrease in the expression of the desired genes.

[0084] When holo-transferrin was removed, GATA1 levels decreased from 1370 to 967, HBA1 levels decreased from 688 to 500, GYPA levels decreased from 330 to 170, and TFRC levels decreased from 2883 to 1703. This factor was found to be important for the induction of HBA1 and GATA1, as removal of knockout serum reduced HBA1 expression from 688 to 520 and GATA1 expression changed from 1357 to 1221.

[0085] AICAR, an AMPK agonist, was found to be an important factor for the upregulation of HBA1 and GYPA. When AICAR was removed, the level of HBA1 dropped from 689 to 569, and the level of GYPA dropped from 337 to 256. The addition of SR1 has an effect on the expression of HBA1 as well as on the expression of glycophorin A and B. When SR1 was removed, the expression of HBA1 dropped from 700 to 597.

[0086] Example 3 : Flow cytometric validation of cell culture media for the induction of erythroid progenitor cells derived from hematopoietic stem cells To validate the developed formulations described in Example 1, cells were treated with Stage 1 and Stage 2 media versus literature media and flow cytometry was used to assess biomarker expression at the end of each stage.

[0087] Stage 1 Recipe To validate the Stage 1 formulation described in Example 1, cord blood derived CD34+ cells were expanded in Stage 1 GATA1 bipotent progenitor induction medium for 4 or 5 days and flow cytometry was used to assess expression of hematopoietic progenitor markers. For comparison with Stage 1 GATA1 expressing bipotent progenitor medium, control cells were also expanded in a literature described differentiation medium (IL3 10 ng / mL, hydrocortisone 1 uM, SCF 100 ng / mL, and EPO 6 U / mL) commonly used to promote differentiation into RBCs.

[0088] Based on the literature, it is possible to identify megakaryocyte / erythroid progenitor cells (MEP cells) using various combinations of markers, as described, for example, by Lin et al. - CD34 + CD38 中 / 低 / CD45RA - (Sanada et al. (2016) Blood 128:923-933; Debili et al. (1996) Blood 88:1284-1296) or - CD34 + CD38 + CD123 - CD45RA -(Cimato et al. (2016) Cytometry B. Clin. Cytom. 90:415-423). Expression of all the above markers was assessed and complemented by megakaryocytic and erythroid end markers as well. Of these, CD34 is expressed in the original HSC population and its expression decreases during differentiation into either lineage. Additional markers were assessed: CD41, a megakaryocytic marker also known as integrin A2B (ITGA2B); CD235 (glycophorin), which is expressed only in erythroid cells; and CD71 (TRFC, transferrin receptor C), whose expression increases substantially during erythroid differentiation but is also expressed during the GATA1-expressing progenitor stage. Fully differentiated erythroid cells either do not express CD71 or express low levels of CD71.

[0089] After cells were grown for 4 or 5 days, flow cytometry analysis was performed to evaluate the immunophenotype of CD34 cells grown in GATA1+ bipotent cell medium. Flow cytometry analysis confirmed the efficiency of the formulation in promoting HSC to progenitor cell conversion. As shown in Figures 6A-6B, the relative percentage of cells that are CD71+ is comparable on days 4 and 5 using either medium. The mean fluorescence intensity (MFI) of CD71 reflects the expression level of the target, and Stage 1 medium caused a significant increase in protein expression. The levels of CD71 were higher in Stage 1 medium compared to the literature medium on both days 4 and 5. Glycophorin, also called CD235 and a marker of final erythroid commitment, was low in both media on day 4, but on day 5, approximately 10% of cells were CD235+ when Stage 1 medium was used, compared with 1.64% of cells when the literature medium was used, suggesting that Stage 1 medium is capable of accelerating differentiation to a committed erythroid lineage.

[0090] Figures 7A-7B show staining for CD34, CD38, CD123, CD71, CD45RA, and CD41 in cells grown for 4 or 5 days in Stage 1 medium (dark grey) and in cells grown for 4 or 5 days in literature medium (light grey). Levels of CD41 / ITGA2B, a commitment marker for the platelet lineage, were low or absent in both conditions at day 5. At day 5, levels of CD34 were similar in both conditions, suggesting that progenitor properties were maintained. Expression of CD38 was relatively high in cells grown using literature medium at days 4 and 5. Previous studies (Sanada et al., 2016; Debili et al., 1996) have shown that erythroid progenitors are CD38+, while bipotential progenitors (megakaryocyte / erythroid progenitors) are low or negative for CD38. 7A-7B also show that the majority of cells were negative for CD45RA and CD123 in both media (CD45RA at day 5: approx. 15% with literature medium vs. approx. 11% with Stage 1 medium; CD45RA at day 4: 39% with literature medium vs. 28% with Stage 1 medium; CD123 at day 5: 7.6% with literature medium vs. 1.1% with Stage 1 medium; CD123 at day 4: approx. 6.6% with literature medium vs. approx. 10% with Stage 1 medium). Granulocyte / monocyte progenitors are CD45RA + and since both common myeloid progenitors and granulocytic / monocytic progenitors are CD123+, these markers demonstrate that interfering myeloid lineages are not induced using the induction conditions described above.

[0091] Stage 2 Recipe To validate the formulation for stage 2 described in Example 1, cord blood derived CD34+ cells were grown in stage 1 medium for 4 days, and then grown in stage 2 medium for 3, 5, and 7 days, and flow cytometry analysis was used to evaluate the expression of erythroid cell markers. Because knockout serum has a proprietary formula and is expensive, we also tested the same formulation with the knockout serum removed and 0.5% albumax added instead, which is the main component of knockout serum. Albumax is a lipid-loaded bovine serum albumin. In addition, to compare with stage 2 medium, cells were grown using literature media for differentiation into RBCs (stage 1: IL3 10 ng / mL, hydrocortisone 1 uM, SCF 100 ng / mL, and EPO 6 U / m; stage 2: SCF 50 ng / mL, EPO 3 U / mL, and 200 ug / mL holotransferrin). Expression of CD34, which is expressed in HSCs and whose expression decreases during differentiation, was also evaluated, whereas CD235 is expressed by red blood cells. Expression of CD71 increases substantially during differentiation into RBCs, but it decreases during later stages of differentiation.

[0092] As shown in Figures 8A-8C, flow cytometry analysis confirmed the efficiency of Stage 2 medium in promoting the conversion of MEP cells to erythroid progenitors. More importantly, Stage 2 medium with albumax promoted more rapid differentiation (higher expression of CD235) when compared to the literature formulation. The results in Figure 8A show that at day 3, the percentage of cells expressing CD71 and CD235 was lower with the literature medium compared to Stage 2 medium (10% vs. 23% and 29%). As shown in Figure 8B, at day 5, Stage 2 medium promoted more rapid differentiation when compared to the literature medium. At this time point, 70% of cells were double positive for CD71 and CD235 in Stage 2 medium compared to 34% in the literature medium. Finally, as shown in Figure 8C, at day 7, Stage 2 medium again performed better than the literature medium, resulting in 87% of cells being double positive for CD71 and CD235 compared to 59% for the literature medium. Taken together, this data indicates that Stage 2 medium is faster, promotes more efficient conversion to the erythroid lineage, and is less expensive compared to the literature protocol.

[0093] Enucleation is one of the final steps in human RBC differentiation. To measure cell enucleation during stage 2, a cell membrane permeable DNA dye, DRAQ5, was used, followed by flow cytometry analysis. The results are shown in Figures 9A-9C. As expected, enucleation was not observed in any of the conditions tested, as it occurs too early in this differentiation process.

[0094] To develop a cost-effective basal medium for RBC differentiation, various compositions of basal medium were tested and compared with the performance of Stemline II. The performance of the basal medium was tested during the process of differentiation at stage 2 (our stage 2 formulation). One composition of basal medium in particular performed similarly to StemLine II with respect to differentiation. The components of this basal medium are shown in Table 3 below. As evidenced in FIG. 10 showing flow cytometry analysis for CD71 and CD235, the differentiation profile of both media was similar; however, when the exemplary basal medium of Table 3 was used, 2-fold more proliferation was observed compared to Stemline II medium.

[0095] Table 3: Exemplary basal medium composition TIFF2024542842000004.tif52128

[0096] To further refine the Stage 2 formulation, further modeling experiments were performed using the same factors as the Stage 2 formulation but testing different concentrations of key factors such as EPO and holotransferrin. In addition, since lipid input is important for RBC differentiation, a commercial cholesterol supplement (Sigma) was tested. The results are shown in Figure 11. Optimization for maximum expression of HBA showed that higher concentrations of holotransferrin (600 ug / mL) and EPO (4 U / mL) caused higher expression of HBA. Cholesterol supplement also had a positive effect on HBA expression. Quantification of cell number showed that adding cholesterol supplement and increasing EPO (4 U / mL) and holotransferrin (600 ug / mL) in the Stage 2 formulation promoted higher proliferation compared to the control.

[0097] Example 4 : Differentiation potential of megakaryocytic / erythroid progenitor cells derived from hematopoietic stem cells To investigate the potential of MEP cells for differentiation, CD34+ HSCs were cultured in Stage 1 medium (described in Example 1) for 4 days. Then, using HD-DoE as described in Example 1, 96 different combinations of effectors (total 12) were made in basal medium, which were added to the cells and allowed to differentiate further. After 3 days, RNA extraction was performed and gene expression was modeled as previously described. In this lineage challenge experiment, the following 12 factors were tested: HB-EGF, optiferin, SR1, knockout serum, ibuprofen, GM-CSF, holotransferrin, EPO, PD102807, neuregulin 1, THI0019, and AICAR. Gene-specific models were obtained as described above and the optimal conditions related to the induction of downstream lineages were similarly investigated.

[0098] To analyze the model, we focused on the expression of genes expressed in committed erythroid progenitors and fully differentiated erythrocytes, such as HBG2, HBA, HBB, GYPA, GYPB, EPOR, ALAD, TFRC, among others. Among these genes, HBG2, HBA, HBB code for hemoglobin; GYPA, GYPB are glycophorins, EPOR (EPO receptor), ALAD (codes for the rate-limiting enzyme for heme synthesis in erythrocytes). The results are summarized in FIG. 12. One model revealed upregulation of all the above-mentioned genes, as well as CA2, ALAS2, GATA1, ICAM4, TAL1, and MLLT3, several of which have been previously shown to be associated with the erythroid lineage. This experiment demonstrated the ability of MEP cells obtained using Stage 1 medium to commit to the erythroid lineage and activate terminal genes. In this model, we show elevated hemoglobin expression, with HBG2 expression of approximately 156335 after normalization representing the production of extremely high amounts of hemoglobin mRNA.

[0099] Next, experiments similar to those described above were performed to challenge the cells towards the megakaryocyte / platelet lineage; however, instead of 12 factors, 8 factors were used, resulting in 48 different combinations of effectors. The factors included pathway-regulating inputs commonly used to induce differentiation into platelets, and were enriched with others that we hypothesized may regulate the platelet lineage, such as: TPO, SCF, VEGF, JQ1, abatrombopag, pyruvate, knockout serum replacement media supplement, and IL6. To analyze the models, we looked at the expression of genes expressed in megakaryocyte progenitors, such as PF4, ITGA2b, FLI1, ZFPM1, etc. One model, the results of which are summarized in FIG. 13, in particular revealed a significant upregulation of all the genes mentioned above, suggesting commitment to the platelet lineage. Based on this model, high expression of PF4, approximately 6339, was observed, and other known genes expressed in megakaryocytes were similarly upregulated, demonstrating full commitment to the megakaryocyte lineage. Taken together, this data indicates that HSCs expanded in Stage 1 medium for 4 days produce MEP cells that have the potential to differentiate into two lineages: erythroid and megakaryocyte, depending on subsequent lineage-directing inputs.

[0100] Equivalent Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein and it is intended that the appended claims cover such equivalents.

Claims

1. A method for producing human GATA1+ megakaryocyte / erythroid progenitor (MEP) cells, comprising culturing human CD34+ hematopoietic stem cells (HSCs) in a culture medium containing an IL3R pathway agonist, a TGFβ pathway agonist, an AHR pathway antagonist, a RET pathway antagonist, and an AKT pathway antagonist from day 0 to day 4 to obtain human GATA1+ MEP cells.

2. The method of claim 1, wherein the human GATA1+ MEP cells are further cultured in a culture medium containing an AHR antagonist, an iron source, an EPOR agonist, an AMPK agonist, and a lipid source on days 4 to 9 to obtain human CD71+CD235+CD34- erythroid progenitor cells.

3. 3. The method of claim 1 or 2, wherein the HSCs are derived from umbilical cord blood.

4. 3. The method of claim 1 or 2, wherein the HSCs are derived from bone marrow or peripheral blood.

5. The method of any one of claims 1 to 4, wherein the IL3R pathway agonist is IL-3.

6. The method of claim 5, wherein IL-3 is present in the culture medium at a concentration in the range of 5 to 15 ng / ml.

7. The method of claim 5, wherein IL-3 is present in the culture medium at a concentration of 10 ng / ml.

8. The method of any one of claims 1 to 4, wherein the TGFβ pathway agonist is selected from the group consisting of alantolactone, activin A, TGFB1, and nodal, and combinations thereof.

9. 9. The method of claim 8, wherein the TGFβ pathway agonist is present in the culture medium at a concentration in the range of 500 to 1000 nM.

10. 9. The method of claim 8, wherein the TGFβ pathway agonist is alantolactone, which is present in the culture medium at a concentration of 750 nM.

11. 5. The method of any one of claims 1 to 4, wherein the AHR pathway antagonist is selected from the group consisting of SR1, GNF351, AHR antagonist 5 hemimaleate, AHR antagonist 1, PDM2, BAY 2416964, CH-223191, AHR antagonist 2, AHR antagonist 4, and combinations thereof.

12. The method of claim 11, wherein the AHR pathway antagonist is present in the culture medium at a concentration in the range of 500 to 1000 nM.

13. 12. The method of claim 11, wherein the AHR pathway antagonist is SR1, which is present in the culture medium at a concentration of 750 nM.

14. 5. The method of any one of claims 1 to 4, wherein the RET pathway antagonist is selected from the group consisting of RETki, Lenvatinib, Regorafenib, Pralsetinib, Selpertinib, Lenvatinib Mesylate, RET-IN-4, RPI-1, JNJ38158471, Amuvatinib, TG101209, Regorafenib Hydrochloride, Ilorasertib Hydrochloride, AST487, PF477736, BBT594, AD80, GSK3179106, SPP86, RET-IN-3, WF-47-JS03, RET V804M-IN-1, Trans-Pralsetinib, PZ1, Regorafenib D3, RET-IN-1, ML786 Dihydrochloride, WHI-P180 Hydrochloride, and combinations thereof.

15. The method of claim 14, wherein the RET pathway antagonist is present in the culture medium at a concentration in the range of 500 to 1000 nM.

16. The method of claim 14, wherein the RET pathway agonist is a RETki, which is present in the culture medium at a concentration of 750 nM.

17. The AKT pathway antagonist is selected from the group consisting of MK2206, GSK690693, Perifosine (KRX-0401), Ipatasertib (GDC-0068), Capivasertib (AZD5363), PF-04691502, AT 7867, Triciribine (NSC154020), ARQ751, Milansertib (ab235550), Borussertib, Cerisertib, Akti1 / 2, CCT128930, A 674563, PHT 427, Miltefosine, AT 13148, ML 9, BAY 1125976, Oridonin, TIC10, Pectolinarin, Acti IV, 10-DEBC, API-1, SC 66, FPA 124, API-2, urolithin A, and combinations thereof.

18. The method of claim 17, wherein the AKT pathway antagonist is present in the culture medium at a concentration in the range of 50 to 150 nM.

19. 18. The method of claim 17, wherein the AKT pathway antagonist is MK2206, which is present in the culture medium at a concentration of 100 nM.

20. 5. The method of claim 2, wherein the iron source is selected from the group consisting of holotransferrin, FeIII_EDTA, Optferrin, FeSO4, ferrous nitrate, lactoferrin, ferritin, and combinations thereof.

21. 21. The method of claim 20, wherein the iron source is present in the culture medium at a concentration in the range of 150-250 ug / ml.

22. 21. The method of claim 20, wherein the iron source is holotransferrin, which is present in the culture medium at a concentration of 200 ug / ml.

23. The method of any one of claims 2 to 4, wherein the EPOR pathway agonist is selected from the group consisting of and combinations thereof.

24. 24. The method of claim 23, wherein the EPOR pathway agonist is EPO.

25. 24. The method of claim 23, wherein the EPOR pathway agonist is EPO, which is present in the culture medium at a concentration of 2 U / ml.

26. The AMPK pathway agonist is selected from the group consisting of AICAR, metformin, BC1618, malvidin-3-O-arabinoside chloride, A-769662, MK8722, bempedoic acid, AICAR phosphate, phenformin hydrochloride, EX229, gingerol, cadinol B, PF06409577, flufenamic acid, GSK621, urolithin B, MK3903, chitosan oligosaccharide, palmitoelaidic acid, O-304, amarogentin, 7-methoxyisoflavone, EB-3D, buformin hydrochloride, platycodin D, ZLN024 hydrochloride, danthron, Ampkinone, ginkgolide C The method of any one of claims 2 to 4, wherein the steroid is selected from the group consisting of: gomisin J, demethylenebernerine, ASP4132, IM156, vacarin, MOTS-c (human) acetate, kahweol, AMPK activator 4, malein, euphorbia steroid, simirasemoside C, metformin D6 hydrochloride, MT6378, RSVA405, nepodin, 3α-hydroxymogrol, AMPK activator 1, YLF-466D, buformin, IQZ23, galesin hydrochloride, karanjin, COH-SR4, HL271, ZLN024, EB-3D, and combinations thereof.

27. 27. The method of claim 26, wherein the AMPK pathway agonist is present in the culture medium at a concentration in the range of 50-150 uM.

28. 27. The method of claim 26, wherein the AMPK pathway agonist is AICAR, which is present in the culture medium at a concentration of 100 uM.

29. 5. The method of any one of claims 2 to 4, wherein the lipid source is selected from the group consisting of Albumax, free fatty acids, lysophosphatidylcholine triacylglycerides, phosphatidylcholine, phosphatidic acid, cholesterol, sphingomyelin, knockout serum replacement, Lipid Mixture 1™, Chemically Defined Lipid Concentrate™, bovine serum albumin, human serum albumin, and combinations thereof.

30. 30. The method of claim 29, wherein the lipid source is Albumax.

31. 30. The method of claim 29, wherein the lipid source is Albumax, which is present in the culture medium at a concentration of 0.5%.

32. 1. A method for generating human CD71+CD235+CD34- erythroid progenitor cells, comprising: (a) culturing human CD34+ hematopoietic stem cells (HSCs) in a culture medium containing an IL3R pathway agonist, a TGFβ pathway agonist, an AHR pathway antagonist, a RET pathway antagonist, and an AKT pathway antagonist on days 0 to 4 to obtain human GATA1+ MEP cells; and (b) further culturing the human GATA1+ MEP cells in a culture medium containing an AHR antagonist, an iron source, an EPOR agonist, an AMPK agonist, and a lipid source on days 4 to 9 to obtain human CD71+CD235+CD34- erythroid progenitor cells. The method comprising:

33. 33. The method of claim 32, wherein in step (a), the IL3R pathway agonist is IL-3, the TGFβ pathway agonist is alantolactone, the AHR pathway antagonist is SR1, the RET pathway antagonist is RETki, and the AKT pathway antagonist is MK2206.

34. 34. The method of claim 33, wherein in step (a), IL-3 is present in the culture medium at a concentration of 10 ng / ml, alantolactone is present in the culture medium at a concentration of 750 nM, SR1 is present in the culture medium at a concentration of 750 nM, RETki is present in the culture medium at a concentration of 750 nM, and MK2206 is present in the culture medium at a concentration of 100 nM.

35. 33. The method of claim 32, wherein in step (b), the AHR pathway antagonist is SR1, the iron source is holotransferrin, the EPOR pathway agonist is EPO, the AMPK pathway agonist is AICAR, and the lipid source is Albumax.

36. 36. The method of claim 35, wherein in step (b), SR1 is present in the culture medium at a concentration of 750 nM, holotransferrin is present in the culture medium at a concentration of 200 ug / ml, EPO is present in the culture medium at a concentration of 2 U / ml, AICAR is present in the culture medium at a concentration of 100 uM, and Albumax is present in the culture at a concentration of 0.5%.

37. A culture medium for obtaining human GATA1+ megakaryocytic / erythroid progenitor (MEP) cells, comprising an IL3R pathway agonist, a TGFβ pathway agonist, an AHR pathway antagonist, a RET pathway antagonist, and an AKT pathway antagonist.

38. A culture medium for obtaining human CD71+CD235+CD34- erythroid progenitor cells comprising an AHR antagonist, an iron source, an EPOR agonist, an AMPK agonist, and a lipid source.

39. An isolated cell culture of human GATA1+ megakaryocyte / erythroid progenitor (MEP) cells, the culture comprising human GATA1+ MEP cells cultured in a culture medium containing an IL3R pathway agonist, a TGFβ pathway agonist, an AHR pathway antagonist, a RET pathway antagonist, and an AKT pathway antagonist.

40. 1. An isolated cell culture of human CD71+CD235+CD34- erythroid progenitor cells, the culture comprising human CD71+CD235+CD34- erythroid progenitor cells cultured in a culture medium comprising an AHR antagonist, an iron source, an EPOR agonist, an AMPK agonist, and a lipid source.

41. 2. Human GATA1+ megakaryocyte / erythroid progenitor (MEP) cells produced by the method of claim 1.

42. 33. A human CD71+CD235+CD34- human erythroid progenitor cell produced by the method of claim 2 or claim 32.